Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis


Por: Gao, YH, Xi, HQ, Wei, B, Cui, JX, Zhang, KC, Li, H, Cai, AZ, Shen, WS, Li, JY, Rosell, R, Chao, J, Chen, TH, Klempner, SJ, Qiao, Z, Chen, L and Gastric Canc Collaborative Grp

Publicada: 26 nov 2019 Ahead of Print: 26 nov 2019
Resumen:
Background: Reports regarding liquid biopsy and gastric cancer (GC) have emerged rapidly in recent decades, yet their prognostic value still remains controversial. This study was aimed to assess the impact of liquid biopsy, including circulating tumor cells (CTCs) and cell-free nucleic acids, on GC patients' prognosis. Methods: PubMed, Medline, EMBASE, and ClinicalTrial.gov databases were searched for studies that report GC patient survival data stratified by CTC/circulating tumor DNA (ctDNA)/circulating miRNAs' status. The hazard ratios (HRs) and their 95% confidence intervals (CIs) for patients' overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS) were recorded or calculated depending on circulating target status. Results: We initially identified 4,221 studies, from which 43 were eligible for further analysis, comprising 3,814 GC patients. Pooled analyses showed that detection of certain CTCs, ctDNA, and circulating miRNA was associated with poorer OS (CTCs: HR = 1.84, 95%CI 1.50-2.26, p < 0.001; ctDNA: HR = 1.78, 95%CI 1.36-2.34, p < 0.001; circulating miRNA: HR = 1.74, 95%CI 1.13-2.69, p < 0.001) and DFS/PFS (CTCs: HR = 3.39, 95%CI 2.21-5.20, p < 0.001; ctDNA: HR = 2.38, 95%CI 1.31-4.32, p = 0.004; circulating miRNA: HR = 3.30, 95%CI 2.39-4.55, p < 0.001) of GC patients, regardless of disease stage and time point at which sample is taken (at baseline or post-treatment). Conclusions: The presence of CTCs and/or cellular components identifies a group of GC with poorer prognosis. Among circulating markers, CTCs demonstrated a stronger and more stable predictive value for late-stage disease and among Mongolian populations with GC. Less data are available for ctDNA and miRNA; however, their presence may also reflect aggressive biology and warrants further prospective study.

Filiaciones:
Gao, YH:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

 Chinese Peoples Liberat Army Gen Hosp, Gen Surg Inst, Beijing, Peoples R China

Xi, HQ:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

Wei, B:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

 Chinese Peoples Liberat Army Gen Hosp, Gen Surg Inst, Beijing, Peoples R China

Cui, JX:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

Zhang, KC:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

Li, H:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

Cai, AZ:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

 Chinese Peoples Liberat Army Gen Hosp, Gen Surg Inst, Beijing, Peoples R China

Shen, WS:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

 Nanjing Mil Command, Nanjing Gen Hosp, Nanjing, Jiangsu, Peoples R China

Li, JY:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

 Chinese Peoples Liberat Army Gen Hosp, Gen Surg Inst, Beijing, Peoples R China

:
 Germans Trias & Pujol Hlth Sci Inst & Hosp, Catalan Inst Oncol, Barcelona, Spain

Chao, J:
 City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

Chen, TH:
 Chinese Acad Sci, Univ CAS, Canc Hosp, Zhejiang Prov Off Canc Prevent & Control,ICBM,Dep, Hangzhou, Zhejiang, Peoples R China

Klempner, SJ:
 Angeles Clin & Res Inst, Los Angeles, CA USA

 Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

Qiao, Z:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

Chen, L:
 Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China

 Chinese Peoples Liberat Army Gen Hosp, Gen Surg Inst, Beijing, Peoples R China
ISSN: 2234943X





Frontiers in Oncology
Editorial
Frontiers Media S.A., AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND, Suiza
Tipo de documento: Review
Volumen: 9 Número:
Páginas: 1222-1222
WOS Id: 000501849300001
ID de PubMed: 31850190
imagen gold, Green Published

MÉTRICAS